InvestorsHub Logo

CaptBeer

02/18/22 1:20 PM

#371085 RE: lettruthringout #371081

No added benefit? What about 25% RRR overall when added to statin? 28%MI 30% stroke. 29% death. WTF?

Whalatane

02/18/22 1:28 PM

#371088 RE: lettruthringout #371081

LTRO. please correct if I have this wrong ...but my reading is

Adults with elevated triglycerides (≥ 150 mg/dL) and high cardiovascular risk to reduce the risk of cardiovascular events

Appropriate comparator therapy:



The above group ...roughly 800,000 patients are covered ....but if you are simply high cardio risk and your TG's are lower than 150 mg/dl ...you are not covered .

This is what I've seen more recently in the US as well among a couple of friends who had MI's , now stented ...but not on Vascepa .
Why ?
TG's under 150mg/dl on optimal statin therapy

Kiwi

couldbebetter

02/18/22 1:31 PM

#371090 RE: lettruthringout #371081

If that is accurate then management in Europe screwed up again.
What a waste to have such a great drug in seemingly incompetent hands!

Whalatane

02/18/22 2:06 PM

#371096 RE: lettruthringout #371081

LTRO. on reading the google translate from Laurent ...they are saying that LDL levels could have been lowered further ( max statin dose or adding ezetimibe to drive LDL below 70 and closer to 55 mg/dl ) therefore AMRN has not proven benefit from the R-IT trial .
Just my take
Kiwi